Zotepin

Structural formula
General
Non-proprietary name	Zotepin
other names	2- (8-chlorodibenzo [ b, f ] thiepin-10-yloxy) - N , N -dimethylethylamine ( IUPAC )
Molecular formula	C 18 H 18 ClNOS
Brief description	colorless crystals
External identifiers / databases
CAS number 26615-21-4 EC number 662-775-7 ECHA InfoCard 100.189.143 PubChem 5736 ChemSpider 5534 DrugBank DB09225 Wikidata Q226905
Drug information
ATC code	N05 AX11
Drug class	Atypical neuroleptics
properties
Molar mass	331.86 g · mol -1
Physical state	firmly
Melting point	90-91 ° C
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed GHS labeling of hazardous substances Caution H and P phrases H: 302-400 P: 273
Toxicological data	306 mg kg −1 ( LD 50 ,  rat ,  oral )
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Zotepine is a drug that is used to treat schizophrenic psychoses . Pharmacologically it belongs to the class of atypical neuroleptics , chemically it belongs to the dibenzepines . The plasma half-life of zotepine is approximately 12 hours in humans.

indication

Zotepine is indicated for the treatment of psychoses of the schizophrenic form a circle.

application

The daily dose is divided into several individual doses. In the case of hepatic insufficiency , renal insufficiency and elderly patients, the dose should be reduced according to the degree of the disease. Zotepine, like other neuroleptics, should be used with caution in patients with a history of epilepsy or epileptoid seizures. If the epilepsy worsens (increased frequency of seizures, worsened seizure severity, etc.), a dose adjustment may be necessary.

Contraindications

Zotepine must not be used in case of hypersensitivity to the active ingredient or to structurally similar substances such as neuroleptics of the phenothiazine and thioxanthene type. Therapy with Zotepine is also contraindicated in the case of acute poisoning with psychotropic drugs , alcohol or opiates , impairment of the blood-forming ( haematopoietic ) system and during pregnancy and breastfeeding. Due to a lack of therapeutic experience, children and adolescents under the age of 18 should be excluded from treatment with Zotepin.

Side effects

Often tiredness, occasionally dizziness, headache and changes in the EEG occur. Epilepsy-like seizures can occur in appropriately disposed patients, especially in higher doses. A malignant neuroleptic syndrome develops very rarely (with fever, rigor , akinesia , vegetative derailment, clouding of consciousness up to a coma).

→ Main article: Atypical neuroleptic

Trade names

Zotepin was commercially available in Germany and Austria under the name Nipolept.

On September 1, 2010, Sanofi-Aventis GmbH stopped selling Nipolept because it could no longer obtain raw materials that met the quality requirements.

See also

• List of antipsychotics

Individual evidence

1. ↑ ^{a b} Entry on Zotepin. In: Römpp Online . Georg Thieme Verlag, accessed on November 10, 2014.
2. ↑ ^{a b} Zotepine data sheet from Sigma-Aldrich , accessed on April 26, 2011 ( PDF ).
3. ↑ Entry on Zotepine in the ChemIDplus database of the United States National Library of Medicine (NLM)
4. ↑ Focus on Zotepine
5. ↑ Red List Online, as of August 2009.
6. ↑ AGES-PharmMed, as of August 2009.
7. ↑ Distribution of Nipolept® is discontinued. Report in the Ärzteblatt , 2010; 107 (33): A-1587.

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !